Study of ANAVEX®2-73-AD-004 in confirmatory Alzheimer's disease
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Blarcamesine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
Most Recent Events
- 05 Apr 2025 According to an Anavex Life Sciences media release, Prof. Dr. Timo Grimmer is the National Coordinating Investigator for the blarcamesine Phase IIb/III ANAVEX2-73-AD-004 study.
- 24 May 2023 New trial record